Gene targeting techniques for Huntington's disease

被引：18

作者：

Fields, Eric ^{[1
]}

Vaughan, Erik ^{[1
]}

Tripu, Deepika ^{[1
]}

Lim, Isabelle ^{[1
]}

Shrout, Katherine ^{[1
]}

Conway, Jessica ^{[1
]}

Salib, Nicole ^{[1
]}

Lee, Yubin ^{[1
]}

Dhamsania, Akash ^{[1
]}

Jacobsen, Michael ^{[1
]}

Woo, Ashley ^{[1
]}

Xue, Huijing ^{[2
]}

Cao, Kan ^{[1
,2
]}

机构：

[1] Univ Maryland, Gemstone Honors Program, College Pk, MD 20742 USA

[2] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA

来源：

AGEING RESEARCH REVIEWS | 2021年 / 70卷

关键词：

Huntington's disease; Allele-specific targeting; Prime editing; SNPs; MUTANT HUNTINGTIN; CAG REPEAT; GUT MICROBIOTA; MOUSE MODEL; RNA; MECHANISMS; THERAPY; PHOSPHORYLATION; INACTIVATION; CILIOGENESIS;

D O I：

10.1016/j.arr.2021.101385

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Huntington's disease (HD) is an autosomal neurodegenerative disorder caused by extended trinucleotide CAG repetition in the HTT gene. Wild-type huntingtin protein (HTT) is essential, involved in a variety of crucial cellular functions such as vesicle transportation, cell division, transcription regulation, autophagy, and tissue maintenance. The mutant HTT (mHTT) proteins in the body interfere with HTT's normal cellular functions and cause additional detrimental effects. In this review, we discuss multiple approaches targeting DNA and RNA to reduce mHTT expression. These approaches are categorized into non-allele-specific silencing and allele-specificsilencing using Single Nucleotide Polymorphisms (SNPs) and haplogroup analysis. Additionally, this review discusses a potential application of recent CRISPR prime editing technology in targeting HD.

引用

页数：8

共 50 条

[41] Molecular Pathogenesis in Huntington's Disease
Illarioshkin, S. N.
Klyushnikov, S. A.
Vigont, V. A.
Seliverstov, Yu. A.
Kaznacheyeva, E. V.
BIOCHEMISTRY-MOSCOW, 2018, 83 (09) : 1030 - 1039
[42] Therapeutic Advances for Huntington's Disease
Kumar, Ashok
Kumar, Vijay
Singh, Kritanjali
Kumar, Sukesh
Kim, You-Sam
Lee, Yun-Mi
Kim, Jong-Joo
BRAIN SCIENCES, 2020, 10 (01)
[43] Gene Dysregulation in Huntington's Disease: REST, MicroRNAs and Beyond
Johnson, Rory
Buckley, Noel J.
NEUROMOLECULAR MEDICINE, 2009, 11 (03) : 183 - 199
[44] Targeting Huntington's disease through histone deacetylases
Gray, Steven G.
CLINICAL EPIGENETICS, 2011, 2 : 257 - 277
[45] Transcriptional Dysregulation in Huntington's Disease: The Role in Pathogenesis and Potency for Pharmacological Targeting
Pogoda, Aleksandra
Chmielewska, Natalia
Maciejak, Piotr
Szyndler, Janusz
CURRENT MEDICINAL CHEMISTRY, 2021, 28 (14) : 2783 - 2806
[46] Targeting Sirtuin-1 in Huntington's Disease: Rationale and Current Status
Duan, Wenzhen
CNS DRUGS, 2013, 27 (05) : 345 - 352
[47] Cell and gene therapy for Huntington's disease
Song, Jihwan
TISSUE ENGINEERING PART A, 2022, 28 : 346 - 346
[48] Huntington's disease
Rollnik, J. D.
NERVENARZT, 2015, 86 (06): : 725 - 735
[49] Transgenic Mouse Models of Parkinson's Disease and Huntington's Disease
Skaper, Stephen D.
Giusti, Pietro
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2010, 9 (04) : 455 - 470
[50] Neuroimaging Techniques in Huntington's Disease: A Critical Review
Farag, Mena
Knights, Harry
Scahill, Rachael I.
Mccolgan, Peter
Estevez-Fraga, Carlos
MOVEMENT DISORDERS CLINICAL PRACTICE, 2025,

← 1 2 3 4 5 →